Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Eikon Therapeutics
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07262619CT.gov EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| eik1005 (this asset) | Eikon Therapeutics | P1/2 | CCC · 48 |
| Rivoceranib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P4 | BBB |
| Fluorouracilum | I-Mab Biopharma US Limited | P4 | BB |
| Oxaliplatin | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Irinotecan | Shenzhen Xinhe Biomedical | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Epirubicin | Rondo Therapeutics | P3 | BB |
+42 more in the Gastric Cancer cohort
Other indications for eik1005
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P1/2 | CCC · 48 |
| Gastroesophageal Junction Adenocarcinoma | — | P1/2 | CCC · 48 |
| Endometrial Carcinoma | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. eik1005 in Gastric Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eik1005-gastric-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →